Pittsburgh, PA, United States of America

William E Klunk

This inventor holds 19 USPTO granted patents and 4 published patent applications, plus 4 CIPO patents and 5 EPO patents, primarily in Alzheimer's Imaging. Top assignee: University of Pittsburgh. Active years: 2000-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: William E Klunk. Retrieved from https://idiyas.com/inventor/william-e-klunk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 4)

% Patents Active = 73.7

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 5

Average Co-Inventor Count = 2.7

ph-index = 7

Forward Citations = 273(Granted Patents)

Company Filing History:

19 out of 1,962

University of Pittsburgh

patents

Years Active: 2000-2018

Loading Chart...

Areas of Expertise:

Thioflavin Derivatives

Benzothiazole Compounds

Amyloid Imaging

Alzheimer's Disease

In Vivo Imaging

Surrogate Markers

Amyloid Deposits

Isotopically-Labeled Compounds

Chrysamine G Derivatives

Diagnostic Methods

Anti-Amyloid Therapies

Nitrogen-Linked Compounds

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10137210 - Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2018-11-27),

2. 9833458 - Thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2017-12-05),

3. 9808541 - Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2017-11-07),

4. 9134328 - Methods of using benzothiazole derivative compounds and compositions (2015-09-15),

5. 8911707 - Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2014-12-16),

6. 8691185 - Benzothiazole derivative compounds, compositions and uses (2014-04-08),

7. 8580229 - Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies (2013-11-12),

8. 8404213 - Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2013-03-26),

9. 8343457 - Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies (2013-01-01),

10. 8236282 - Benzothiazole derivative compounds, compositions and uses (2012-08-07),

11. 8147798 - Amyloid imaging as a surrogate marker for efficacy of anti-amyloid therapies (2012-04-03),

12. 8138360 - Isotopically-labeled benzofuran compounds as imaging agents for amyloidogenic proteins (2012-03-20),

13. 7854920 - Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2010-12-21),

14. 7351401 - Thioflavin derivatives for use in the antemortem diagnosis of Alzheimers disease and in vivo imaging and prevention of amyloid deposition (2008-04-01),

15. 7270800 - Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition (2007-09-18),

Title: The Innovative Mind of William E Klunk: Pioneering Alzheimer's Research

Introduction:

William E Klunk, a distinguished inventor hailing from Pittsburgh, PA, has made significant contributions to the field of medical research, particularly in the area of Alzheimer's disease. With an impressive portfolio of 19 patents to his name, Klunk has cemented his legacy as a trailblazer in the development of novel diagnostic and treatment methods for neurodegenerative disorders.

Latest Patents:

Among Klunk's latest patents is the groundbreaking invention of thioflavin derivatives for use in the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition. These derivatives are pivotal in the early detection and monitoring of diseases characterized by the accumulation of neuritic plaques, such as Alzheimer's disease, Down's Syndrome, and familial Alzheimer's disease.

Career Highlights:

Throughout his illustrious career, William E Klunk has been affiliated with esteemed institutions like the University of Pittsburgh - of the Commonwealth System of Higher Education. His relentless pursuit of innovation and commitment to advancing medical science have earned him recognition as a pioneering figure in the realm of neurology and Alzheimer's research.

Collaborations:

Klunk's innovative work has been accentuated by collaborations with esteemed colleagues such as Chester A Mathis, Jr and Yanming Wang. Together, they have synergized their expertise to push the boundaries of medical research and drive forward the development of cutting-edge solutions for complex neurological disorders.

Conclusion:

In conclusion, William E Klunk stands as a beacon of innovation in the sphere of medical research, particularly in the realm of Alzheimer's disease. His visionary approach to problem-solving and unwavering dedication to scientific advancement have paved the way for transformative breakthroughs in the diagnosis and treatment of neurodegenerative conditions. Klunk's pioneering spirit serves as an inspiration to future generations of inventors and researchers, propelling the field of medical science towards new horizons of possibility and discovery.

Profile summary based on public USPTO records.